Linfoma a grandes células anaplásico asociado a implantes mamarios

  • M Zerga Hospital Alemán
Palabras clave: linfoma a grandes células anaplásico ALK negativo, lmplantes mamarios texturados, seroma tardío

Resumen

El linfoma a grandes células anaplásico asociado a implantes mamarios (BIA-ALCL) es un tipo infrecuente de linfoma T periférico, CD30 positivo y ALK negativo, que se presenta en la mayor parte de los casos como una colección líquida alrededor de un implante mamario o de su cápsula(1).

El primer caso de BIA-ALCL fue reportado en 1997 en una mujer de 41 años que desarrolló un linfoma T periférico a grandes células anaplásico CD30 + en la cápsula fibrosa que rodeaba un implante mamario de superficie texturada, efectuado con fines estéticos. A partir de allí se publicó la primera serie compuesta por 51 casos(2).

En el 2016, la WHO lo reconoció como una entidad provisional(3), y puso énfasis en el manejo quirúrgico de la misma.

Recientemente, las Guías de la NCCN incluyeron un consenso de diagnóstico y tratamiento del BIA-ALCL, en el que participaron oncólogos clínicos, cirujanos plásticos, radioterapeutas y cirujanos oncológicos provenientes de las instituciones miembros de la NCCN, a fin de orientar a la comunidad médica sobre el reconocimiento de esta entidad y su manejo adecuado.

Referencias bibliográficas

1. Clemens M, Horwitz S. NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant Associated Anaplastic large Cell Lymhoma. Aesthetic Surgery Journal. 37 (3): 285-289.
2. Keech JA Jr, Creech BJ. Anaplastic T cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg. 1997; 100: 554-555.
3. Swerdlow S et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasm. Blood. 2016; 127: 2375-2390.
4. Horwitz S et al. NCCN Guidelines Insights: Non Hodgkin´s lymphomas. Version 2-2018. Breast Implant Associated ALCL. J Natl Compr Canc Netw. 14, 2018.
5. Leberfinger A, Behar B, Williams N et al. Breast Implant-Associated Anaplastic Large Cell Lymphoma. A Systematic Review. JAMA Surg. 2017 Dec 1;152(12):1161-1168.
6. Administration, U.F.a.D. Anaplastic Large Cell Lymphoma (ALCL) in Women with Breast Implants: Preliminary FDA Findings and Analyses. 2011.
7. Nava MB, Adams WP, Botti G et al. MBN 2016 Aesthetic Breast Meeting BIA-ALCL Consensous Conference Report. Plast Reconstr Surg. 2018; 141: 40-48.
8. Doren E et al. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plastic Reconstr Surg. 2017; 139: 1042-1050.
9. McGuire P, Reisman N, Murphy D. Risk Factor Analysis for Capsular Contracture, Malposition, and Late Seroma in Subjets Receiving Natrelle 410 Form-Stable Silicone Breast Implants. Plastic Reconstr Surg. 2017; 139: 1-9.
10. Maxwell G, Van Natta B, Bengtson B et al. Ten years results from the Natrelle 410 anatomical form-stable silicone breast implant core study. Aesthetic Surgery Journal 2015; 35: 145-155.
11. Clemens M. Discussion: Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High surface area textured implants are associated with increased risk. Plastic Reconstr Surg. 2017; 140: 660-662.
12. Vase M et al. Breast implants and anaplastic large cell lymphoma: a danish population-based cohort study. Cancer Epidemiol Biomakers Prev. 2013; 22: 2126-2129.
13. Mehta-Shah N, Clemens M, Horwitz S. How I treat breast implant associated Anaplastic Large Cell Lymphoma. Blood. 2018 Nov 1;132(18):1889-1898.
14. Brody G, et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plastic Reconstr Surg. 2015; 135: 695-705.
15. Blombery P et al. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma. Haematologica. 2016; 101: 387-390.
16. Di Napoli A et al. Targeted next generation sequencing of breast implant- associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signaling pathway genes, TP53 and DNMT3A. Br J Haematol. 2018 Mar;180(5):741-744.
17. Hu H, Johani K, Almatroudi A et al. Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large Cell Lymhoma. Plast Reconstr Surg. 2016; 137: 1659-1669.
18. Clemens M et al. Complete Surgical Excision is Essential for the Management of Patients with Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2016 Jan 10;34(2):160-8.
19. Leberfinger A et al. Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review. JAMA Surgery. 2017; 152:1161-1168.
20. Bautista-Quach M, Nademanee A, Weisenburger D et al. Implant associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules. Clin Breast Cancer. 2013; 13: 492-495.
21. Chihara D, Fanale M. Management of Anaplastic Large Cell Lymphoma. Hematol Oncol Clin. 2017; 31: 209-222.
22. Miranda RN, Aladily TN, Prince HM et al. Breast implant-associated anaplastic large cell lymphoma: long term follow up of 60 patients. JCO. 2014; 32 (2): 114-120.
23. Van Dorp M, Kindt J, Mertens M et al. Novel technique for sampling of breast implant-associated seroma in anaplastic large cell lymphoma. Plast Reconstr Surg Glob Open. 2016; 4: 1-2.
24. Clemens M, Medeiros L, Butler C et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large cell lymphoma. Journal of Clinical Oncology. 2018; 34: 160-168.
Publicado
2019-01-21
Sección
Artículo de revisión